Literature DB >> 15021146

Acetabular osteoarticular allograft after Ewing's sarcoma resection.

Nikil N Verma1, Ken N Kuo, Steven Gitelis.   

Abstract

Ewing's sarcoma of the pelvis traditionally has been a difficult problem in orthopaedic oncology. Multiple studies have had inferior outcomes when compared with outcomes of patients with similar stage disease involving only the extremities. A major reason for this discrepancy is the difficulty associated with resection and reconstruction of pelvic tumors. Often the tumors are deemed nonresectable and are treated with chemotherapy and radiation or radiation alone. Patients treated in this manner have lower 5-year survival rates, higher local recurrence rates, and multiple long-term complications. The case of a 4-year-old girl with Ewing's sarcoma of the left hemi-pelvis is reported. Combined with adjuvant chemotherapy, this patient was treated with resection followed by osteoarticular allograft reconstruction. At 2 years followup, the patient was disease-free with an excellent functional outcome.

Entities:  

Mesh:

Year:  2004        PMID: 15021146     DOI: 10.1097/00003086-200402000-00024

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Reconstruction with customized, 3D-printed prosthesis after resection of periacetabular Ewing's sarcoma in children using "triradiate cartilage-based" surgical strategy:a technical note.

Authors:  Dongze Zhu; Jun Fu; Ling Wang; Zheng Guo; Zhen Wang; Hongbin Fan
Journal:  J Orthop Translat       Date:  2021-03-26       Impact factor: 5.191

2.  Clinical study of 3D printed personalized prosthesis in the treatment of bone defect after pelvic tumor resection.

Authors:  Lin Xu; Hao Qin; Jia Tan; Zhilin Cheng; Xiang Luo; Haitao Tan; Wenhua Huang
Journal:  J Orthop Translat       Date:  2021-06-30       Impact factor: 5.191

Review 3.  Acetabular roof lesions in children: a descriptive study and literature review.

Authors:  Jinkui Wang; Zhongliang Wang; Jiaqiang Qin
Journal:  BMC Musculoskelet Disord       Date:  2020-08-24       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.